Clinical Trials on Bladder Abnominalies

Total 3095 results

Instituto do Cancer do Estado de São Paulo

Recruiting

Safety Analysis and Oncological Outcomes in HoLERT vs TURBT

Bladder Cancer | Bladder Urothelial Carcinoma

Brazil
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients (ASCERTAIN)

Non-muscle Invasive Bladder Cancer

China
Rapamycin Holdings, Inc. dba Emtora Biosciences
National Cancer Institute (NCI)

Recruiting

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Non-muscle Invasive Bladder Cancer

United States
Pfizer

Completed

Drug Use Investigation for Toviaz

Overactive Bladder (OAB)
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Detrol LA In Men With Overactive Bladder.

Overactive Bladder (OAB)

United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
Medstar Health Research Institute
Columbia University; University of Michigan; University of New Mexico; Methodist...

Terminated

PTNS vs Botox of Refractory OAB (TROOP)

Overactive Bladder (OAB)

United States
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Urinary Bladder Cancer

Netherlands
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) (PREFER)

Overactive Bladder (OAB)

United States, Canada
Merck Sharp & Dohme LLC

Terminated

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Overactive Bladder | Overactive Urinary Bladder
Mansoura University

Completed

Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer (NMIBCIVT)

Carcinoma of Urinary Bladder, Superficial

Egypt
Michael Chancellor, MD
William Beaumont Hospitals

Completed

Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.

Overactive Bladder

United States
FKD Therapies Oy

Completed

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Superficial Bladder Cancer
Loyola University
Astellas Pharma Inc

Completed

Validation of a Real-time Urodynamic Measure of Urinary Urgency

Overactive Bladder Syndrome

United States
Beijing Pins Medical Co., Ltd

Unknown

A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique

Refractory Overactive Bladder
Azienda Ospedaliero-Universitaria Consorziale Policlinico...

Completed

Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
National University Hospital, Singapore
National Medical Research Council (NMRC), Singapore

Completed

Combined Use of BCG and Interferon Alpha in Bladder Cancer

Carcinoma of Urinary Bladder, Superficial

Singapore
Maastricht University Medical Center

Unknown

Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Netherlands
Varian, a Siemens Healthineers Company
Rigshospitalet, Denmark; Herlev Hospital

Recruiting

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach (ARTIA-Vesica)

Muscle-Invasive Bladder Carcinoma

Denmark
Elypta
Lund University

Recruiting

AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study (AUR93A)

Muscle-Invasive Bladder Carcinoma

Sweden, Denmark, Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital...

Not yet recruiting

Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.

Muscle-Invasive Bladder Carcinoma
Ruijin Hospital

Not yet recruiting

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma

China
IRCCS San Raffaele
Bristol-Myers Squibb

Recruiting

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo)

Muscle-Invasive Bladder Carcinoma

Italy
Yonsei University

Not yet recruiting

a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients

Muscle-Invasive Bladder Carcinoma

Korea, Republic of
C2i Genomics
Fox Chase Cancer Center; Baylor College of Medicine; New York University; The Cleveland... and other collaborators

Terminated

Clinical Performance Evaluation of the C2i-Test

Muscle-Invasive Bladder Carcinoma

United States
University Hospital Inselspital, Berne
AstraZeneca

Terminated

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin (NITIMIB)

Muscle-invasive Bladder Cancer

Switzerland
GlaxoSmithKline

Completed

Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer

Neoplasms, Urinary Bladder

Belgium
Balgrist University Hospital
Swiss National Science Foundation

Completed

Heart Rate Variability (HRV) in Patients With Neurogenic Detrusor Overactivity (NDO) Before and After Botulinum Neurotoxin Type A (BoNT/A) Intradetrusor Injections (HRV/Botox)

Bladder Disorder, Neurogenic

Switzerland
Sanofi

Completed

Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology (ALFACHIP)

Urinary Bladder Neurogenic

Serbia, United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Recurrent Bladder Carcinoma | Stage I Bladder Cancer | Stage 0a Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma

United States
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Roswell Park Cancer Institute

Recruiting

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Metastatic Bladder Carcinoma | Locally Advanced Bladder Carcinoma | Unresectable Bladder Carcinoma

United States
Assaf-Harofeh Medical Center

Unknown

Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity

Overactive Bladder Syndrome | Bladder Outlet Obstruction | Benign Prostate Enlargement | Stress Incontinence (Female) (Male) | Bladder Disease

Israel
Sesen Bio, Inc.

Completed

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Urinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors

United States, Canada
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
Mansoura University

Recruiting

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

Non-Muscle Invasive Bladder Cancer

Egypt
Augusta University

Not yet recruiting

Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial

Overactive Bladder | Overactive Bladder Syndrome
Association Francaise d'Urologie

Not yet recruiting

AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU)

Non-Muscle-Invasive Bladder Cancer
Uro-1 Medical

Recruiting

Use of Repris Needle in Bladder Injection

Overactive Bladder Syndrome

United States
Fisiocore LC,SL

Recruiting

Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder.

Overactive Bladder Syndrome

Spain
National Taiwan University Hospital

Completed

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Overactive Bladder Syndrome

Taiwan
National and Kapodistrian University of Athens

Completed

Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)

Overactive Bladder (OAB)

Greece
CG Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)

Non Muscle Invasive Bladder Cancer

United States, Korea, Republic of
Taipei Medical University Shuang Ho Hospital

Completed

Effect of Ureteral Stents Length and Location on Related Symptom

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Taiwan
Astellas Pharma Singapore Pte. Ltd.

Completed

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Overactive Bladder (OAB)

Korea, Republic of, Taiwan
Ataturk Training and Research Hospital

Unknown

Effects of Kinesio Taping Application in Women With Overactive Bladder

Overactive Bladder Syndrome

Turkey
Astellas Pharma Inc

Completed

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Overactive Bladder (OAB)

Japan
Catalan Institute of Health

Completed

Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron

Overactive Bladder Syndrome
Buddhist Tzu Chi General Hospital

Unknown

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Overactive Bladder Syndrome

Taiwan
Poitiers University Hospital

Unknown

Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer (IPOI vs IPOP)

Non Muscle-invasive Bladder Cancer

France
University of Oklahoma

Completed

Vaginal Electrical Stimulation Versus Neuromodulation (Estim)

Refractory Overactive Bladder

United States

Clinical Trials on Bladder Abnominalies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations